Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.60 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880582 | 0.91 | TACR1 (0.50) | TACR1TAS2R14 | |
| SCHEMBL6868748 | 0.87 | TACR1 (0.60) | TACR1TAS2R14 | |
| SCHEMBL6866303 | 0.85 | CETP (0.53) | TACR1 | |
| SCHEMBL6016692 | 0.82 | TACR1 (0.46) | TACR1 | |
| SCHEMBL6870284 | 0.79 | RAB9A (0.51) | TACR1 | |
| SCHEMBL6016462 | 0.75 | CETP (0.43) | TACR1 | |
| SCHEMBL6872779 | 0.75 | TACR1 (1.00) | TACR1 | |
| SCHEMBL30755384 | 0.74 | MYC (0.71) | — | |
| SCHEMBL656 | 0.74 | MYC (0.71) | — | |
| SCHEMBL16127840 | 0.73 | KMT2A (0.65) | TACR1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171419-B1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6552088-B2 | 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor | HOFFMANN-LA ROCHE INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020040060-A1 | Biphenyl derivatives | BOS MICHAEL (CA) | 2002-04-04 | — | — | US | disclosed |
| EP-1171419-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6291465-B1 | Biphenyl derivatives | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000053572-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040060-A1 | Biphenyl derivatives | NR1H4, NR1H2, NR1H3 | TACR1 16/4885TAS2R14 2248/4885P2RX1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.